Imaging Where a Labeled Drug Goes in Inflammatory Bowel Disease
Tests a glowing-labeled version of risankizumab to see where it reaches in Crohn or colitis.
Plain-language title generated from the registry record
Registry title: Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
Key facts
- Where
- Groningen, NetherlandsSee the site
- Phase
- Phase 1/2
Where in Netherlands
- University Medical Center GroningenGroningen, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Center Groningen
- Trial code
- NCT06606808EU 2024-515358-25-00
- Record updated
- 5 March 2025
- Original description
Crohn\'s Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory response in IBD upon binding to its receptor. Primary non-response to risankizumab is high in both CD and UC. Currently, there are no predictors of response to risankizumab and the actual mechanism of action has not yet been elucidated. To gain better understanding of the drug targeting of risankizumab in IBD, the University Medical Center Groningen (UMCG) developed fluorescently labeled risankizumab (risankizumab-800CW). This study aims to assess the safety and the optimal dose of risankizumab-800CW to visualize and potentially quantify the local drug concentration and predict treatment response in IBD patients using in vivo and ex vivo fluorescence molecular imaging (FMI).Read full original descriptionShow less
Investigating the Safety, Feasibility, and Optimal Dose of Risankizumab-800CW for Visualizing Drug Targeting in Inflammatory Bowel Disease
Crohn\'s Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory response in IBD upon binding to its receptor. Primary non-response to risankizumab is high in both CD and UC. Currently, there are no predictors of response to risankizumab and the actual mechanism of action has not yet been elucidated. To gain better understanding of the drug targeting of risankizumab in IBD, the University Medical Center Groningen (UMCG) developed fluorescently labeled risankizumab (risankizumab-800CW). This study aims to assess the safety and the optimal dose of risankizumab-800CW to visualize and potentially quantify the local drug concentration and predict treatment response in IBD patients using in vivo and ex vivo fluorescence molecular imaging (FMI).
Inclusion: Established IBD diagnosis; Active disease: clinically active disease of the bowel is defined clinically as at least mild activity using dedicated scoring indices or biochemically active disease as defined by a fecal calprotectin \> 60 μg/g; Patients must be eligible for risankizumab therapy; Minimum age of 18 years; Written informed consent; Clinical indication for an endoscopic procedure; Established IBD diagnosis; Patients must be on risankizumab therapy for at least 14 weeks; Minimum age of 18 years; Written informed consent; Clinical indication for an endoscopic procedure.
Exclusion: Prior anti-IL23-specific therapy (IL23/IL12 combination therapy is not an exclusion criteria); Medical or psychiatric conditions that compromise the patient's ability to give informed consent; Active extra gastrointestinal manifestations of Crohn's disease (e.g. uveitis or pyoderma gangrenosum at vital locations); Medical or psychiatric conditions that compromise the patient's ability to give informed consent; Active extra gastrointestinal manifestations of Crohn's disease (e.g. uveitis or pyoderma gangrenosum at vital locations); A female study patient of premenopausal age who does not use any reliable form of contraception at the time of risankizumab-800CW administration and the following 10 weeks; A female study patient of premenopausal age who does not use any reliable form of contraception at the time of risankizumab-800CW administration and the following 10 weeks; A female study patient who is pregnant or provides breastfeeding; A female study patient who is pregnant or provides breastfeeding.